



March 4, 2019

Ronald Myers, PhD.,
Science Editor
JoVE

Dear Dr. Myers:

On behalf of my co-author I wish to submit to JoVE our manuscript entitled “Approaches to Manufacture Chimeric Antigen Receptor (CAR) T cells and Assess their Function for Adoptive Immunotherapy” for consideration. Our work builds upon our extensive experience in the development and clinical evaluation of chimeric antigen receptor (CAR) therapies for B cell malignancies and the discovery of biomarkers predictive of response to CD19-specific CAR T (CTL019) cells, including the ability of these cells to expand and persist post-infusion (Sci Transl Med. 2015 Sep 2;7(303):303ra139). This work is based on our recently published manuscript (Cancer Immunol Res. 2018 Sep;6(9):1100-1109) that showed the culture duration is an important determinant of function of CAR T cells in vivo. Importantly, the manufacturing process presented in this paper has been validated under current Good Manufacturing Process conditions, used in our clinical trials.

We believe that our manuscript will be of great interest to investigators in the field of cellular therapy as it comprehensively presents the process of generating CAR T cells which is one major factor affecting T cell immunotherapy. We hope that you will appreciate its value and consider our manuscript for publication in your journal.

Sincerely,

A handwritten signature in black ink that reads "Saba Ghassemi".

Saba Ghassemi, PhD